anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To provide a viral respiratory infectious disease preventing or treating agent of a novel component.SOLUTION: The present invention is characterized by the followings. 1. Glucosylceramide and/or viral respiratory infectious disease preventing or treating agent having glucosylceramide as an active ingredient. 2.Viral respiratory infectious disease preventing or treating agent having β-sitosterol glycoside as an active ingredient. 3. Viral respiratory infectious disease preventing or treating agent described in 1 or 2 above in which the viral respiratory infectious disease is influenza.SELECTED DRAWING: None
ETHNOPHARMACOLOGICAL RELEVANCE: Acanthopanax senticosus (Rupr. & Maxim.) Harms (AS), also known as Eleutherococcus senticosus (Rupr. & Maxim.) Maxim. or Siberian ginseng, has a rich history of use as an adaptogen, a substance believed to increase the body's resistance to stress, fatigue, and infectious diseases. As a traditional Chinese medicine, AS is popular for its cardioprotective effects which can protect the cardiovascular system from hazardous conditions. Doxorubicin (DOX), on the other hand, is a first-line chemotherapeutic agent against a variety of cancers, including breast cancer, lung cancer, gastric cancer, and leukemia, etc. Despite its effectiveness, the clinical use of DOX is limited by its side effects, the most serious of which is cardiotoxicity. Considering AS could be applied as an adjuvant to anticancer agents, the combination of AS and DOX might exert synergistic effects on certain malignancies with mitigated cardiotoxicity. Given this, it is necessary and meaningful to confirm whether AS would neutralize the DOX-induced cardiotoxicity and its underlying molecular mechanisms.
AIM OF THE STUDY: This paper aims to validate the cardioprotective effects of AS against DOX-induced myocardial injury (MI) while deciphering the molecular mechanisms underlying such effects.
MATERIALS AND METHODS: Firstly, the cardioprotective effects of AS against DOX-induced MI were confirmed both in vitro and in vivo. Secondly, serum pharmacochemistry and network pharmacology were orchestrated to explore the in vivo active compounds of AS and predict their ways of functioning in the treatment of DOX-induced MI. Finally, the predicted mechanisms were validated by Western blot analysis during in vivo experiments.
RESULTS: The results demonstrated that AS possessed excellent antioxidative ability, and could alleviate the apoptosis of H9C2 cells and the damage to mitochondria induced by DOX. In vivo experiments indicated that AS could restore the conduction abnormalities and ameliorate histopathological changes according to the electrocardiogram and cardiac morphology. Meanwhile, it markedly downregulated the inflammatory factors (TNF-α, IL-6, and IL-1β), decreased plasma ALT, AST, LDH, CK, CK-MB, and MDA levels, as well as increased SOD and GSH levels compared to the model group, which collectively substantiate the effectiveness of AS. Afterward, 14 compounds were identified from different batches of AS-dosed serum and selected for mechanism prediction through HPLC-HRMS analysis and network pharmacology. Consequently, the MAPKs and caspase cascade were confirmed as primary targets among which the interplay between the JNK/Caspase 3 feedback loop and the phosphorylation of ERK1/2 were highlighted.
CONCLUSIONS: In conclusion, the integrated approach employed in this paper illuminated the molecular mechanism of AS against DOX-induced MI, whilst providing a valuable strategy to elucidate the therapeutic effects of complicated TCM systems more reliably and efficiently.
NEW MATERIAL:Antibiotic MK16 substance shown by the formula. This antibiotic is a compound comprising N-methyl-L-valine as a constituent amino acid. USE:Having antibacterial activity against gram-positive bacteria and useful as an antimicrobial agent. PREPARATION:A fungus belonging to the genus Fusarium, capable of producing antibiotic MK1688 substance, is cultured and antibiotic MK1688 substance is collected from the culture mixture thereof. Especially submerged culture is optimum as the culture. The culture temperature is 10-30 deg.C, especially 20-27 deg.C. In the production, the accumulation reaches the optimum both in shaking culture and tank culture usually in 3-10 days, the culture is stopped at that time and the aimed substance is isolated and purified from the culture solution.
PURPOSE:To provide water-containing cosmetic containing propylene carbonate as a low-toxic, low-irritant agent for preventing contamination with microorganisms such as fungi, yeasts, and bacteria over a wide pH range. CONSTITUTION:Water-containing cosmetics, pref. an emulsion-type cosmetic selected from milky lotion, cream, foundation, eye shadow, and cheek rouge, or a nonemulsion-type cosmetic selected from beauty wash, and shampoo, are compounded with propylene carbonate as an agent for preventing contamination with microorganisms. The amount of propylene carbonate is pref. >=2wt% based on the water in the water-containing cosmetics. Propylene carbonate is low-toxic and low-irritant to the skin, soluble in water, and inhibits the contamination with fungi, yeasts, and bacteria. The solubility in water is kept constant independent of the pH of the solution. Accordingly, propylene carbonate is suitable as an additive to water- containing cosmetics for controlling the contamination of the skin with microorganisms.
Patients are observed for 6 months. If disease progresses during first 6 months, patients may receive interleukin-12 as in arm I. Patients without disease progression within first 6 months may also then receive interleukin-12 as in arm I. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for toxicity only until interleukin-12 is discontinued.
Many adolescents under 18 years old who sell sex are at elevated risk for sexually transmitted infection (STI) acquisition, which may persist into adulthood. There has been limited study of the burden of the risks and vulnerabilities among women who started selling sex as adolescents across Sub-Saharan Africa. In this study, a Adult female sex workers (FSW) recruited through respondent-driven sampling in five cities in Cameroon from December 2015 to October 2016 completed a questionnaire and human immunodeficiency virus (HIV) and syphilis testing. Multivariable logistic regression analysis controlling for age was used to identify factors associated with reporting selling sex before age 18. Selling sex before age 18 was reported by 11.5% (256/2,220) of FSW. Initiation of selling sex as an adolescent was positively associated with experiencing dysuria (adjusted odds ratio [aOR]:1.50, 95% confidence interval [CI]:1.08-2.10) or genital warts (aOR:1.78, 95% CI:1.08-2.94) and negatively associated with prior recent testing for HIV (aOR:0.71, 95% CI:0.53-0.96) or STIs (aOR:0.65, 95% CI:0.44-0.96). Consistent condom use with clients was negatively associated with early initiation of selling sex (aOR:0.58, 95% CI:0.42-0.80), while experience of recent sexual violence was positively associated with early initiation (aOR:1.74, 95% CI:1.15-2.63). There were no independent significant differences in HIV (24.5%) or syphilis (8.3%) prevalence. Given the limited use of HIV and STI testing services by women who sold sex as adolescents, the prevalence of forced sex, condomless sex, and STI symptoms were high. Programs serving FSW should more vigorously aim to serve adolescents and adults who began selling sex early.
Patients receive copanlisib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
the primary out come of this study is to report oral side effects associated with chemo and radiotherapy used for treating head and neck cancer .patient will be enrolled and data will be collected from the national institute of cancer in Egypt. this will be done through filling the modified ( Edmonton Symptom Assessment System) ESAS questionnaire used to asses different oral side effects in cancer patients. history taking and Clinical examination will be done for each patient enrolled in the study after obtaining their consent form by the main investigator. each and every oral manifestations will be measured by a specific scale . the secondary outcome is identified as the assessment of the effect of oral complications on patients' quality of life which will be determined through completing UW-QOL(University of Washington-Quality Of Life) questionnaire version 4.during the study, patient , treatment and tumor variable will be considered and documented .Data collected form the patient and or from medical records will be saved and tabulated on computer for back up and finally statistically analyzed. A power analysis was designed to have adequate power to apply a statistical test of the research question regarding the degree to which oral adverse events can prevail among patients receiving chemotherapy or radiotherapy. According to the results of Minhas, Sadia, et al. -in which prevalence of oral adverse events was (92.6%)- and by adopting a confidence interval of (95%), a margin of error of (3%) with finite population correction; the predicted sample size (n) was a total of (292) cases. Sample size calculation was performed using Epi info for windows version 7.2
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of QALSODY cannot be directly compared to rates in clinical trials of other drugs and may not reflect the rates observed in practice. 

The safety of QALSODY 100 mg was evaluated in 147 patients with SOD1-ALS. The median patient exposure was 119.4 weeks (range from 4 to 212 weeks). QALSODY was evaluated in the placebo-controlled Study 1 and in the open label extension Study 2. In Study 1 Part C, approximately 43% were female; 57% were male; 64% were White and 8% were Asian. The mean age at entry in Study 1 Part C was 49.8 years (range from 23 to 78 years). 

The most common adverse reactions (≥ 10% of patients treated with QALSODY and greater than placebo) were pain, fatigue, arthralgia, CSF white blood cell increased, and myalgia. Table 1 shows the common adverse reactions that occurred in at least 5% of patients treated with QALSODY and at a 5% or higher frequency than placebo. 

Less Common Adverse Reactions

Serious adverse reactions of myelitis and radiculitis; papilledema and elevated intracranial pressure; and aseptic meningitis have occurred in patients treated with QALSODY [see Warnings and Precautions (5.1, 5.2, 5.3)]. 

In the long-term extension study, nonserious adverse reactions of pyrexia have occurred with repeat administration of QALSODY.
C-reactive protein (CRP) has been identified as a possible mediator of the association between periodontitis and various systemic diseases. The presence of periodontitis has been hypothesized as a risk factor for several systemic outcomes, including chronic kidney disease (CKD). Therefore, the aim of this study is to evaluate the impact of non-surgical periodontal treatment on CRP levels and quality of life of patients with chronic kidney disease undergoing hemodialysis (HD) in Santa Maria-RS. A total of 88 patients with severe periodontitis who are on HD therapy will be included in this study. At baseline, periodontal, radiographic, blood test, and quality-of-life questionnaire will be assessed for all patients, after which severe periodontitis will be defined according to the American Association of Periodontology and European Federation of Periodontology. The 88 patients with periodontal disease will be randomized and divided into two groups. One group will receive full mouth non-surgical periodontal treatment (TPNC) and a late treatment group that will receive TPNC only at the end of the study. All patients will receive follow-up of periodontal parameters and blood collection for initial CRP assessment at 3 and 6 months after treatment. Outcome evaluators will be blind to the group the patient belongs to. Patients in the immediate treatment group will receive follow-up oral hygiene instructions and use 0.12% chlorhexidine mouthwash during the first week after treatment.
This test region will receive pretreatment with the fractional CO2 laser (Ultrapulse, DeepFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 7.5 mJ/microbeam (depth 225 µm) and 20% density. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done 3-5mm into the bone apical to the socket according to the manufacturer's instructions. Patients will receive an immediate post-extraction implant without any grafting material in the socket between the residual labial bone and implant surface.
A 20-minute mindful breathing session guided by a trained medical doctor. The session consisted of four 5-minute breathing exercises done consecutively. Participants were instructed to close their eyes and bring their attention to their breathing, and re-direct their attention back to their breathing once they were distracted.
Pregnancy Category C: Sirolimus was embryo/fetotoxic in rats when given in doses approximately 0.2 to 0.5 the human doses (adjusted for body surface area). Embryo/fetotoxicity was manifested as mortality and reduced fetal weights (with associated delays in skeletal ossification). However, no teratogenesis was evident. In combination with cyclosporine, rats had increased embryo/feto mortality compared with sirolimus alone. There were no effects on rabbit development at a maternally toxic dosage approximately 0.3 to 0.8 times the human doses (adjusted for body surface area). There are no adequate and well-controlled studies in pregnant women. Effective contraception must be initiated before sirolimus therapy, during sirolimus therapy, and for 12 weeks after sirolimus therapy has been stopped.
A system for authorizing an external device to access computerized records. The system includes a server. The server includes a computerized records data-store. The computerized records data-store stores multiple computer executable files associated with subjects. The system includes a communication network which facilitates communication between at least two of the subjects, the server, and the external device. The system includes a contextual authorization device for authorizing access to the external device for the computerized records. The contextual authorization device includes a database storing a set of custom rules. The contextual authorization device further includes a Global Positioning System-based tracking device, a credentialing engine, and a user behavior analytics engine. The contextual authorization device further includes an access module to process authorization of the external device for access of the computerized records.
Phase III will pilot test the newly developed app for utility, satisfaction, and preliminary effectiveness in a group of 40 homeless adults with an AUD who are receiving shelter-based treatment. The investigators will compare Phase III participants (i.e., received Metrocare, EMAs, and tailored treatment messages) to Phase I participants (i.e., received Metrocare and EMAs only) to examine the preliminary effectiveness of the app.
Patients in the "anti-CEA CAR-T Cells plus gemcitabine/nab paclitaxel arm" will have achieved at least stable disease during the Bridging Therapy Period with gemcitabine/nab paclitaxel, and will receive the CAR-T cells in Cycles 1 and 3 and the gemcitabine/nab paclitaxel regimen they received during the Bridging Therapy Period in Cycle 2 and Cycles ≥ 4 of the Treatment Period. Treatment will continue until the development of disease progression.
Cohort F3 is an expansion control arm for cohort F2. Participants will receive daratumumab in combination with pomalidomide at the MTD and dexamethasone. NOTE: This cohort is randomized.
FIELD: medicine.SUBSTANCE: invention refers to dentistry, orthopedics and orthodontics and can be used for diagnosing and correcting detected respiratory pathologies combined with a locomotor system pathology when planning orthopedic and/or orthodontic treatment. Performing general and dental history. Dental history includes patient's answers to questions on tooth sensitivity, problems with chewing, speech, jaw joints, occlusion, previous dental or orthodontic treatment, onset of head and neck cramps. Oral cavity examination is performed to obtain Brookscheker data. Epwort is determined for determination of somnolence. Patient's face is photographed with a smile, in a relaxed state, with an open mouth, with relaxed muscles with subsequent determination of aesthetic facial parameters. Aesthetic parameters of the smile are determined, including the evaluation of the combination of the tooth shape, position, size and color, their proportions and symmetry relative to each other and facial components. Locomotor system is examined by electromyography, podoscopy and fluoroscopy. Polysomnographic examination of the patient is performed. It involves a head telo-radiograph in a straight and a lateral projection, an orthopantogram, a computed tomography of a temporomandibular joint. MRI of the head is performed with subsequent processing of the obtained image by means of a computing unit and obtaining on the monitor a three-dimensional image of a patient's head containing an image of teeth and soft tissues of the oral cavity, then the obtained image is analyzed by cephalometry. If observing a pathology of respiratory organs in a combination with a pathology of the locomotor system, the orthopedic and/or orthodontic treatment is combined with osteopathic treatment. Before performing the orthopedic and/or orthodontic treatment, the desired occlusion is simulated on the virtual model of the patient's head by means of the Gamma Dental program, followed by a spinal therapy.EFFECT: method enables reducing functional problems in body operation after correction of occlusion due to complex approach to diagnosis and treatment of human and set of objective functional analysis in various fields of medicine at the stage of treatment planning.1 cl
Rationale: Glioma stem cells (GSCs) have emerged as pivotal drivers of tumor malignancy, sustained by various microenvironmental factors, including immune molecules and hypoxia. In our previous study, we elucidated the significant role of transforming growth factor beta-induced protein (TGFBI), a protein secreted by M2-like tumor-associated macrophages, in promoting the malignant behavior of glioblastoma (GBM) under normoxic conditions. Building upon these findings, the objective of this study was to comprehensively explore the crucial role and underlying mechanisms of autocrine TGFBI in GSCs under hypoxic conditions. Methods: We quantified TGFBI expression in glioma specimens and datasets. In vitro and in vivo assays were employed to investigate the effects of TGFBI on sustaining self-renewal and tumorigenesis of GSCs under hypoxia. RNA-seq and LC-MS/MS were conducted to explore TGFBI signaling mechanisms. Results: TGFBI is preferentially expressed in GSCs under hypoxic conditions. Targeting TGFBI impair GSCs self-renewal and tumorigenesis. Mechanistically, TGFBI was upregulated by HIF1α in GSCs and predominantly activates the AKT-c-MYC signaling pathway in GSCs by stabilizing the EphA2 protein through preventing its degradation. Conclusion: TGFBI plays a crucial role in maintaining the stem cell properties of GSCs in the hypoxic microenvironment. Targeting the TGFBI/EphA2 axis emerges as a promising and innovative strategy for GBM treatment, with the potential to improve the clinical outcomes of patients.
The embodiment of the invention provides a method, a device, equipment and a storage medium for generating an electronic medical record based on a conversation, and relates to the technical field of natural language processing. The electronic medical record generation method comprises the following steps: s1, text data of doctor-patient conversation is obtained. And S2, inputting the text data into a pre-trained text classification model, acquiring the electronic medical record item type of each paragraph, and aggregating the paragraphs with the same electronic medical record item type to acquire the paragraph type set of each electronic medical record item type. And S3, respectively inputting the paragraphs in each paragraph category set into a pre-trained entity extraction model, obtaining the labels of the medical named entities in each paragraph, and forming an entity label pair set. And S4, generating medical record texts according to the entity label pair set and on the basis of the entity relation template, and recording and combining the medical record texts to obtain the electronic medical record. The invention can directly extract information from doctor-patient conversation to generate the electronic medical record with accurate, strict and normative content and according with medical language expression.
Both training conditions will receive a 1.5 day training followed by ongoing supervision while they implement exposure therapy with patients recruited to the study. The first full day will consist of the same foundational information in both conditions. The two conditions will differ in their training focus during the subsequent half-day training. The Behaviorally Enhanced condition will involve therapist engagement in repeated self-exposure and partner-exposure exercises with the goal of targeting and reducing therapists' reservations about using exposure with their patients. The focus of ongoing supervision following the initial 1.5 day training workshop will also differ by condition. The Behaviorally Enhanced condition will include regular sampling and feedback on therapists' remaining reservations about exposure in additional to counseling the implementation of exposure with therapists' patients.
Control subjects receive bone augmentation without decorticalisation (corticotomy) and 1 week postop. OTM.